The University of Pennslyvania has produced a great publication about improving the efficacy of adoptive T-Cell therapy in solid tumours by using 3rd generation CAR-T cells: https://insight.jci.org/articles/view/96976
Gruden et al from University of Pennslyvania show that CD4+ and CD8+ T cells exhibit distinct persistence and effector phenotypes, depending on the identity of specific intracellular signalling domains (ICDs). Those CARs with ICOS and 4-1BB ICDs demonstrated an increased efficacy in solid tumours.
The xCELLigence Real-Time Cell Analsysis (RTCA) system from ACEA Bioscience was used to evaluate the lysis of non–small cell lung L55 tumour cells when treated with CAR T cells over a 20-hour period. Learn More about the advantages of using RTCA for CAR-T https://www.aceabio.com/applications/cancer-immunotherapy/genetically-engineered-t-cell-mediated-cell-killing/
